U.S. Stock Market Movement: Gyre Therapeutics surged on November 16 – Q3 results exceeded expectations, revenue guidance reaffirmed, and F351 launch advanced.
Bitget异动解读2026/11/16 17:11Gyre Therapeutics November 16 Surge Analysis
Keywords: Q3 performance exceeded expectations, revenue guidance reaffirmed, F351 listing progress
1. On November 5, 2026, Gyre Therapeutics announced its Q3 2026 results, with earnings per share at -$0.04, better than the market expectation of -$0.13; sales revenue was $32.934 million, surpassing the market prediction of $28.4 million.
2. On November 5, 2026, the company reaffirmed its fiscal 2026 sales guidance to be between $100.5 million and $111 million.
3. On November 5, 2026, the company disclosed that its core product F351 (hydroxyprogesterone) for the treatment of chronic hepatitis B-related liver fibrosis has had its new drug application accepted by the National Medical Products Administration and has completed an on-site inspection; if approved, it is expected to be launched in the first half of 2027.
(Disclaimer: This content is generated by AI technology based on publicly available information for summary purposes only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Google Releases Ask Admob and Admob Agent AI Tools

Boeing and Philippine Airlines finalize order for up to 20 Boeing 787 aircraft